OPHTHALMODERMA

The Oculo–Cutaneous Interface and the Primary Target Organ of Dermophthalmology (Dermophthalmology)

Category / White Paper      

Issued by: WOD – World Organization of Dermophthalmology

Lead author: Ioannis Tsakalos (John Tsakalos)

Affiliation / Entity: Breath Purity – Ophthalmogen

Place / Year: Athens, 2025 – Conceived in Greece

Version: v1.0 (December 2025)

Status: Position paper / Unifying framework (not a clinical treatment guideline)

Abstract

Ophthalmoderma is proposed as a new foundational concept and as a unified functional micro-ecosystem that integrates dermatologic and ophthalmic structures within the same field of clinical relevance: eyebrows, eyelids, eyelashes, follicles and glands of the lid margin (Zeis, Moll), meibomian glands, and the ocular surface together with the tear film. This field constitutes the Oculo–Cutaneous Interface, i.e., the interface where skin transitions into an ocular system and where the biology of the ocular surface depends directly on cutaneous mechanisms.

From a clinical perspective, Ophthalmoderma is defined as the primary “target organ” of Dermophthalmology, analogous to the role of the periodontium in oral health: it is not “a part,” but the functional substrate that determines stability, comfort, clarity, prevention of inflammation, and long-term quality of life.

This White Paper:

  1. maps the historical and epistemological continuity of Greek medical thought,
  2. introduces a precise anatomical and functional definition of Ophthalmoderma,
  3. links the concept to contemporary high-prevalence conditions (blepharitis, meibomian gland dysfunction/MGD, Demodex blepharitis, ocular rosacea, dry eye disease),
  4. describes impacts on visual quality, aesthetics, and daily functioning,
  5. proposes a framework for prevention, education, and clinical practice for the 21st century.

  1. Introduction

1.1 Why a new concept is needed

Modern humans face a historically new reality: increased screen exposure, environmental pollutants, systematic use of cosmetics around the eyes, aesthetic medicine procedures, and prolonged states of low-grade facial inflammation. In the same time frame, there has been an international surge in symptoms such as burning, dryness, reflex tearing, “heavy eyelids,” morning blurry vision, and chronic discomfort that is often managed in a fragmented way.

The primary weakness of the existing model is not lack of knowledge; it is lack of integration. The periocular region is treated as “eye” by Ophthalmology, as “skin” by Dermatology, as an “aesthetic zone” by Aesthetic Medicine, and as a “surgical field” by Oculoplastics. Yet biology does not operate in isolated islands. Daily clinical reality shows that many of the most common ocular surface symptoms originate at the interface: skin–eyelid–lid margin–glands–tear film.

Ophthalmoderma provides a name, boundaries, and clinical substance to this previously “unnamed” functional system.

1.2 Dermophthalmology position on the eyelid and interdisciplinary collaboration

The study and therapeutic management of the eyelid and the ocular interface belongs primarily to Ophthalmology, as it is directly linked to visual function, tear film stability, and ocular surface health.At the same time, it is recognized that many dermatologic facial conditions manifest in, or involve, the periocular region. This makes collaboration with Dermatology essential for comprehensive patient care.

Dermophthalmology does not change the roles of specialties; it provides a shared scientific framework for understanding and collaboration, aiming to optimize visual quality, comfort, and overall quality of life.

Claim of Novelty / Original Contribution

This White Paper introduces Ophthalmoderma as a clearly defined anatomical and functional entity and establishes it as the primary organ-target of Dermophthalmology. Although the individual components of the ocular interface – namely the ocular surface, eyelids, Meibomian Glands, periocular skin, and the tear film – have been extensively studied within the fields of Ophthalmology and Dermatology, their integration into a single, named, and clinically functional system has not, to date, been articulated in a structured and systematic manner.

The originality of the present work does not lie in the in the introduction of new pathophysiological mechanisms, but rather in the synthetic unification of existing scientific knowledge, the clear establishment of terminology, and the shift of clinical perspective toward an organ–target–based framework. By defining Ophthalmoderma, this paper provides a shared scientific language that bridges medical specialties, clarifies the domain of responsibility of the ocular interface, and creates a foundation for the development of future interdisciplinary protocols, research directions, and public-health prevention strategies.

In this sense, Ophthalmoderam represents a new paradigm of interface-based medical thinking, extending contemporary ocular surface science into a coherent, functional, and clinically applicable framework for the medicine of the 21st century.

  1. Historical framework

2.1 From Greek medical thought to modern integration

Greek medical tradition established two major leaps in the history of medicine:

  • the leap of observation and causality (Hippocratic thought),
  • and the leap of anatomical mapping (the Alexandrian School).

The relevance here is not symbolic but epistemological: Dermophthalmology does not simply “add” another subfield. It revives a core element of medical progress: the integration of structure and function at the level of a target organ.

2.2 The Alexandrian School as a model for “interface thinking”

With the Alexandrian tradition, medicine learned to see boundaries, transitions, and layers. The eyelid and lid margin are not simply “skin over the eye”; they are a transitional zone with glands, follicles, muscles, nerves, and dynamic motion that determines the state of the ocular surface. This is precisely the logic of the Oculo–Cutaneous Interface.

  1. Definition of Ophthalmoderma

3.1 Formal definition

Ophthalmoderma:

The anatomical and functional space that includes, as a unified micro-ecosystem:

  1. the eyebrows,
  2. the eyelid skin and underlying tissues,
  3. the eyelash ring, follicles, and adjacent glands (Zeis, Moll),
  4. the meibomian glands and their orifices at the lid margin,
  5. the ocular surface (conjunctiva, cornea),
  6. the tear film as a functional membrane,
  7. the microbiome and the neuro-immune network of the region.

Ophthalmoderma is the primary regulatory system for tear film stability, comfort, environmental protection, and the aesthetic identity of the gaze.

3.2 Summary formula

Ophthalmoderma = Eyebrows + Eyelids + Eyelashes/Follicles + Glands (Meibomian/Zeis/Moll) + Ocular surface + Tear film + Microbiome/Nerves

  1. The anatomical logic of the Oculo–Cutaneous Interface

4.1 The transitional zone “skin → mucosa → tear membrane”

In the human body, there are few regions where:

  • hairs,
  • exocrine glands,
  • a cutaneous barrier,
  • a mucosal surface,
  • a kinetic pump (blinking),
  • and a thin aqueous–lipid film

coexist in such a small area with such large functional impact.

The lid margin is such a zone. Ophthalmoderma defines this whole zone as a system, not as separate “structures.”

4.2 Meibomian glands as “cutaneous glands that regulate vision”

Meibomian glands are modified sebaceous glands. Their function, however, is not only about skin oiliness; it is about producing the lipid layer of the tear film. Therefore, they constitute the quintessential biological “bridge” between skin and eye—the central organ within Ophthalmoderma.

  1. Embryologic foundation

The skin and critical components of the ocular system share related embryologic origins, while the eyelid region is a highly specialized developmental zone where tissues with different final functions cooperate in a single mechanism of protection and lubrication. This embryologic “kinship” is not theoretical: it explains why periocular skin inflammation can manifest with ocular symptoms and vice versa.

  1. Pathophysiology

 

6.1 Inflammation as a common language

The Ophthalmoderma region functions as a field of neuro-immune convergence. Irritation of eyelid skin, microbiome alteration, obstruction of gland orifices, or burden from cosmetics/pollutants can produce low-grade inflammation that destabilizes:

  • the fluidity and secretion of meibum,
  • blink quality/completeness,
  • tear film stability,
  • and ultimately visual quality.

6.2 Demodex as an “organism of interface”

Demodex (particularly at the follicle and gland level) acts as an interface organism linking cutaneous and ocular inflammation: it may be associated with cylindrical dandruff at the lashes, chronic irritation, orifice dysfunction, recurrent chalazia, and worsening of dry eye. Within Ophthalmoderma, Demodex is not a “detail”; it is an interface factor.

 

6.3 MGD and dry eye as “interface disease”

A large proportion of dry eye disease manifests as tear film instability related to eyelid and gland dysfunction. This shifts the center of gravity: from “not enough tears” to “a dysfunctional Ophthalmoderma that fails to stabilize the film.”

  1. Ophthalmoderma as the “Periodontium of the eye”

The analogy is functional, not poetic.

Periodontium (mouth): a system of gums–ligaments–supporting structures that determines long-term dental health and prevention of inflammation.

Ophthalmoderma (eye): a system of eyelids–glands–lid margin–cutaneous barrier–tear film that determines long-term ocular surface stability.

A major public health shift of the 20th century was the universal adoption of daily oral hygiene as a preventive norm. The corresponding shift of the 21st century may be the universal adoption of daily Ophthalmoderma hygiene as a preventive routine for billions living with interface symptoms (dry eye, blepharitis, irritation, visual instability).

 8. Clinical manifestations and diseases of Ophthalmoderma

Indicative high-frequency clinical domains:

  1. Blepharitis (anterior/posterior): chronic inflammation with significant symptom burden.
  2. Meibomian gland dysfunction (MGD): obstruction/hypofunction with tear film instability.
  3. Ocular rosacea: dermatologic disease with a clear ocular component and frequent underdiagnosis.
  4. Demodex blepharitis: aggravating factor at follicles and the lid margin.
  5. Seborrheic dermatitis of brows/eyelids: often accompanies chronic irritation.
  6. Chalazion / recurrences: association with obstruction and microbial interface load.
  7. Allergic/irritant contact dermatitis from cosmetics: barrier disruption leading to “interface inflammation.”
  8. Aesthetic impacts: dark circles, edema, “tired look,” heaviness, lash weakening.

Common denominator: they do not belong “purely” to one specialty—they belong to Ophthalmoderma.

  1. Ophthalmoderma and aesthetics

The periocular region is the most powerful aesthetic “signal” of the face. Ophthalmoderma health affects:

  • brightness and clarity of the gaze,
  • edema and vascular appearance,
  • lash/brow quality,
  • perceived fatigue and age.

Dermophthalmology does not “aestheticize” medicine. It restores a clinical truth: the aesthetic appearance of this region is a marker of interface physiology (inflammation, barrier status, microcirculation, gland function, tear film stability).

  1. Surgery, preoperative care, and prevention of complications

Within a complete Ophthalmoderma framework, pre- and postoperative interface care becomes central:

  • in refractive surgery (tear stability for reliable measurements and comfort),
  • in oculoplastics (blepharoplasty/functional interventions),
  • in aesthetic procedures that affect blinking, skin, and glands.

The goal is not merely “absence of symptoms,” but stabilization of the ecosystem.

  1. Public health and productivity impact

Dry eye, chronic blepharitis, visual instability, and persistent irritation disproportionately affect:

  • concentration, performance, screen time,
  • driving comfort,
  • sleep quality (especially with burning/discomfort),
  • social confidence and facial self-image.

Ophthalmoderma as a target organ creates space for new preventive protocols (Dermophthalmology protocols) aiming to reduce burden at a population level.

  1. Proposals for integration into education and practical guidance

The institutional value of Ophthalmoderma increases if integrated:

  1. into Ophthalmology and Dermatology training units (an “interface” module),
  2. into consensus clinical texts on blepharitis/MGD/ocular rosacea,
  3. into WOD cross-specialty workshops and sessions with a shared language,
  4. into public education aiming at universal prevention (as occurred with oral hygiene).

Conclusion — A call for 21st-century medicine

Ophthalmoderma is not merely a new term. It is a new clinical way of thinking:

  • it defines an interface previously “scattered” across specialties,
  • it integrates anatomy, physiology, inflammation, aesthetics, and function,
  • it establishes Dermophthalmology as necessary rather than optional.

By establishing Ophthalmoderma as a target organ, the path opens for:

  • clearer diagnosis,
  • better prevention,
  • more stable visual quality,
  • improved quality of life.

At the same time, a historical continuity is reflected: Greece as the place where medical thought learned to unify observation, structure, and function—and where a new paradigm of “interface medicine” can be founded for global ocular and cutaneous health.

Acknowledgements

This work is grounded in the accumulated knowledge and scientific data of the international ophthalmology and dermatology communities, and in foundational contributions by organizations, research groups, and consensus texts that shaped modern understanding of the tear film, ocular surface, and meibomian gland dysfunction (indicatively: TFOS DEWS II, International Workshop on MGD).

We particularly acknowledge the scientists and clinicians who developed methodologies, terminology, and documentation frameworks that make it possible to formulate a unified scientific framework for the Oculo–Cutaneous Interface.

The development of Dermophthalmology as an interdisciplinary field presupposes ongoing collaboration among Ophthalmology, Dermatology, Oculoplastics, Aesthetic Medicine, and related disciplines. This document aspires to serve as a shared language, recognizing that progress is achieved collectively.

Scientific bodies (reference — as a framework for scientific dialogue):

The scientific direction and international networking of the field are strengthened through collaborations and dialogue with Greek and international scientific bodies, including (indicatively): the Hellenic College of Ophthalmology, the HSIOIRS, the Hellenic Ophthalmological Society, the American Academy of Ophthalmology (AAO), the European Society of Cataract & Refractive Surgeons (ESCRS), and the Global Hippocratic Doctors Institute (GDHI).

In addition, regarding the dermatologic dimension of the interface, we acknowledge the broader scientific contribution of the dermatology community and its institutional societies, including (indicatively): the Hellenic Society of Dermatology and Venereology, the European Academy of Dermatology and Venereology (EADV), and the American Academy of Dermatology (AAD).

Note: The mention of organizations is provided as a framework for scientific dialogue and does not imply official endorsement/co-signature of this document unless there is explicit written acceptance.

Conflict of interest statement

The author is a founder/executive of Breath Purity and is associated with the development of products and educational protocols related to ocular interface care and pioneer of the Dermophthalmology concept. This document is educational and scientific in purpose and is based on published literature.

References

Core sources on tear film & ocular surface

  1. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15(3):276–283.
  2. Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II Pathophysiology Report. Ocul Surf. 2017;15(3):438–510.
  3. Nichols KK, Foulks GN, Bron AJ, et al. The International Workshop on Meibomian Gland Dysfunction. Invest Ophthalmol Vis Sci. 2011;52(4):1917–2085.
  4. Pflugfelder SC, Stern ME. Biological functions of tear film. Exp Eye Res. 2020;197:108115.
  5. King-Smith PE, Nichols JJ, Nichols KK, et al. Contributions of evaporation and other mechanisms to tear film thinning. Invest Ophthalmol Vis Sci. 2008;49(11):4794–4801.

Meibomian glands & eyelid function

  1. Bron AJ, Tiffany JM, Gouveia SM, Yokoi N, Voon LW. Functional aspects of the tear film lipid layer. Exp Eye Res. 2004;78(3):347–360.
  2. Blackie CA, Solomon JD, Greiner JV, et al. The relationship between dry eye symptoms and lipid layer thickness. Cornea. 2009;28(7):789–794.
  3. Finis D, Hayajneh J, König C, et al. Evaluation of meibomian gland dysfunction. Ophthalmologe. 2013;110(6):533–540.
  4. Knop E, Knop N, Millar T, et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Anatomy, Physiology, and Pathophysiology. Invest Ophthalmol Vis Sci. 2011;52(4):1938–1978.

Eyelid skin, dermatology & inflammation

  1. Akpek EK, Merchant A, Pinar V, Foster CS. Ocular rosacea: patient characteristics and follow-up. Ophthalmology. 1997;104(11):1863–1867.
  2. Vieira AC, Höfling-Lima AL, Mannis MJ. Ocular rosacea—a review. Arq Bras Oftalmol. 2012;75(5):363–369.
  3. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye. Cornea. 2012;31(5):472–478.
  4. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483–1494.
  5. Norn MS. External eye disease and eyelid disorders in dermatology. Dermatol Clin. 1992;10(2):307–321.

Demodex, microbiome & biofilm

  1. Gao YY, Di Pascuale MA, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Br J Ophthalmol. 2005;89(9):1168–1173.
  2. Fromstein SR, Harthan JS, Patel J, Opitz DL. Demodex blepharitis. Optometry. 2018;89(6):336–344.
  3. Liang L, Safran S, Gao Y, et al. Ocular demodicosis. CurrOpin Allergy Clin Immunol. 2010;10(5):505–510.
  4. Murphy O, O’Dwyer V, Lloyd-McKernan A. The effect of lid hygiene on Demodex infestation. Eye Contact Lens. 2020;46(2):77–81.

Eyelashes, aerodynamics & vision

  1. Amador GJ, Hu DL. Eyelashes divert airflow to protect the eye. J R Soc Interface. 2015;12(102):20141294.
  2. Pult H, Riede-Pult BH. Impact of tear film instability on visual acuity. Cornea. 2012;31(10):1135–1140.
  3. McMonnies CW. Incomplete blinking. J Optom. 2007;1(2):58–65.

Blinking, neurophysiology & digital strain

  1. Tsubota K, Nakamori K. Dry eyes and video display terminals. N Engl J Med. 1993;328:584.
  2. Portello JK, Rosenfield M, Chu CA. Blink rate, incomplete blinks, and computer vision syndrome. Optom Vis Sci. 2013;90(5):482–487.
  3. Argilés M, Cardona G, Pérez-Cabré E, Rodríguez M. Blink rate and incomplete blinks in dry eye patients. Ophthalmic Physiol Opt. 2015;35(3):289–296.

Prevention, hygiene & clinical protocols

  1. Trattler WB, Majmudar PA, Donnenfeld ED, et al. The Prospective Health Assessment of Cataract Patients’ Ocular Surface (PHACO) study. ClinOphthalmol. 2017;11:1423–1430.
  2. Holland EJ, Darvish M, Nichols KK, Jones L, Karpecki PM. Management of ocular surface disease before cataract surgery. J Cataract Refract Surg. 2016;42(12):1774–1785.
  3. McDonald MB, Sheppard JD. Lid hygiene and ocular surface optimization. Eye Contact Lens. 2016;42(1):2–7.

Visual quality & tear film

  1. Montes-Micó R, Alió JL. Tear film instability and higher-order aberrations. J Cataract Refract Surg. 2004;30(8):1636–1642.
  2. Koh S. Mechanisms of visual disturbance in dry eye. Cornea. 2016;35(Suppl 1):S83–S88.
  3. Goto E, Yagi Y, Matsumoto Y, Tsubota K. Visual function in dry eye patients. Am J Ophthalmol. 2002;133(2):181–186.

Aging, skin barrier & ocular surface

  1. Farage MA, Miller KW, Elsner P, Maibach HI. Functional and physiological characteristics of the aging skin. Aging ClinExp Res. 2008;20(3):195–200.
  2. Kottner J, Lichterfeld A, Blume-Peytavi U. Maintaining skin barrier function. Skin Pharmacol Physiol. 2013;26(4–6):187–195.

Public health & quality of life

  1. Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15(3):334–365.
  2. Miljanović B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143(3):409–415.

Foundational integration concepts

  1. Knop E, Korb DR, Blackie CA, et al. The lid margin is a distinct anatomical unit. Ocul Surf. 2011;9(2):79–91.
  2. Sullivan DA, Rocha EM, Aragona P, et al. TFOS DEWS II Sex, Gender, and Hormones Report. Ocul Surf. 2017;15(3):284–333.
  3. Willcox MDP, Argüeso P, Georgiev GA, et al. TFOS DEWS II Tear Film Report. Ocul Surf. 2017;15(3):366–403.

Additional supportive references

  1. Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol. 2008;146(3):350–356.
  2. McCulley JP, Shine WE. The lipid layer: the outer surface of the ocular surface tear film. Biosci Rep. 2001;21(4):407–418.
  3. Baudouin C. Inflammation and the ocular surface. J Fr Ophtalmol. 2008;31(10):S1–S4.
  4. Aragona P, Rolando M. Towards a dynamic customized therapy for dry eye. Br J Ophthalmol. 2013;97(8):955–960.
  5. Nelson JD, Craig JP, Akpek EK, et al. TFOS DEWS II Introduction. Ocul Surf. 2017;15(3):269–275.
  6. Goto E, Tseng SCG. Tear lipid layer thickness. Cornea. 2003;22(7):707–713.
  7. Korb DR, Henriquez AS. Meibomian gland dysfunction and contact lens intolerance. J Am Optom Assoc. 1980;51(3):243–251.
  8. Eom Y, Lee JS, Kang SY, et al. Correlation between MGD and visual quality. PLoS One. 2013;8(11):e80053.
  9. Baudouin C, Irkec M, Messmer EM, et al. Clinical impact of inflammation in dry eye disease. Ocul Surf. 2018;16(4):427–434.
  10. Schein OD, Munoz B, Tielsch JM, et al. Prevalence of dry eye. Arch Ophthalmol. 1997;115(6):767–774.
  11. Nichols JJ, Mitchell GL, Zadnik K. Performance and repeatability of dry eye tests. Invest Ophthalmol Vis Sci. 2004;45(7):2289–2295.
  12. McMonnies CW. The importance of eyelid function in dry eye disease. ClinExpOptom. 2017;100(3):213–218.
  13. Labbé A, Terry O, Brasnu E, et al. Tear film osmolarity in dry eye disease. Invest Ophthalmol Vis Sci. 2012;53(9):5283–5289.

Contributors / Scientific Committee (in formation)

WOD Scientific Committee (Ophthalmology& Dermatology) — in formation

Clinical & Academic Advisors — to be announced

WOD Working Groups:

  • Tear film & Ocular surface
  • Lid margin & Meibomian gland dysfunction
  • Periocular skin & Inflammation

Demodex& Microbiome